Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Clinical characteristics and prognostic factors in Chinese patients with Hodgkin’s lymphoma

Authors: Ying-Jie Zhu, Yue-Li Sun, Yi Xia, Wen-Qi Jiang, Jia-Jia Huang, Hui-Qiang Huang, Tong-Yu Lin, Zhong-Zhen Guan, Zhi-Ming Li

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

The aim of our study is to investigate the clinical characteristics and prognostic factors in Chinese Hodgkin’s lymphoma patients. It is known that clinical characteristics and epidemiology of Hodgkin’s lymphoma in China are different from Western countries. In total, 137 consecutive, previously untreated patients with Hodgkin’s lymphoma at Sun Yat-Sen University Cancer Center were enrolled. Among these patients, 92 were male and 45 were female, with a median age of 28 (range: 2–76) years. The bimodal age curve of classical Hodgkin’s lymphoma analyzed from our patients was not obvious as the Western population, showing an early peak in 25 years and a second peak in 45 years. Most of the patients (41.6%) were classified as nodular sclerosis classic Hodgkin’s lymphoma. Results showed that the 5-year overall survival, event-free survival, and disease-free survival rates were 97.7, 85.0, and 94.0%, respectively. Lymphopenia at diagnosis was related to poorer overall survival (P = 0.015) and event-free survival (P < 0.001) in all-stage Hodgkin’s lymphoma patients. Multivariate analysis showed that lymphopenia as an independent unfavorable prognostic factor influenced event-free survival (P = 0.015). The international prognostic score ≥ 5 was also the only independent prognostic factor of disease-free survival in advanced-stage patients (P = 0.046). Our findings demonstrated that some clinical characteristics of Hodgkin’s lymphoma in China were different from those in the Western countries. Lymphopenia was an effective prognostic predictor in both early stage and advanced stage.
Literature
1.
go back to reference Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC; 2008. Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC; 2008.
2.
go back to reference Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20:30–44.PubMedCrossRef Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20:30–44.PubMedCrossRef
3.
go back to reference Glaser SL, Jarrett RF. The epidemiology of Hodgkin’s disease. Bailliere’s Clin Haematol. 1996;9:401–16.CrossRef Glaser SL, Jarrett RF. The epidemiology of Hodgkin’s disease. Bailliere’s Clin Haematol. 1996;9:401–16.CrossRef
4.
5.
go back to reference Ji X, Li W. Malignant lymphomas in Beijing. J Environ Pathol Toxicol Oncol. 1992;11:327–9.PubMed Ji X, Li W. Malignant lymphomas in Beijing. J Environ Pathol Toxicol Oncol. 1992;11:327–9.PubMed
6.
go back to reference Aisenberg AC. Problems in Hodgkin’s disease management. Blood. 1999;93:761–79.PubMed Aisenberg AC. Problems in Hodgkin’s disease management. Blood. 1999;93:761–79.PubMed
7.
go back to reference Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. New Engl J Med. 1998;339:1506–14.PubMedCrossRef Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. New Engl J Med. 1998;339:1506–14.PubMedCrossRef
8.
go back to reference Henry-Amar M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC lymphoma cooperative group. Ann Intern Med. 1991;114:361–5.PubMed Henry-Amar M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC lymphoma cooperative group. Ann Intern Med. 1991;114:361–5.PubMed
9.
go back to reference Tubiana M, et al. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer. 1984;54:885–94.PubMedCrossRef Tubiana M, et al. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer. 1984;54:885–94.PubMedCrossRef
10.
go back to reference Tubiana M, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood. 1989;73:47–56.PubMed Tubiana M, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood. 1989;73:47–56.PubMed
11.
go back to reference Duhmke E, et al. Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996;36:305–10.PubMedCrossRef Duhmke E, et al. Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996;36:305–10.PubMedCrossRef
12.
go back to reference Cheson BD, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 1999;17:1244. Cheson BD, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 1999;17:1244.
13.
go back to reference Grillo-Lopez AJ, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol. 2000;11:399–408.PubMedCrossRef Grillo-Lopez AJ, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol. 2000;11:399–408.PubMedCrossRef
14.
go back to reference Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
15.
go back to reference Smolewski P, et al. Prognostic factors in Hodgkin’s disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6:1150–60.PubMed Smolewski P, et al. Prognostic factors in Hodgkin’s disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6:1150–60.PubMed
16.
go back to reference Josting A, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin lymphoma study group. Blood. 2000;96:1280–6.PubMed Josting A, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin lymphoma study group. Blood. 2000;96:1280–6.PubMed
17.
go back to reference Tomita Y, et al. Epstein-Barr virus in Hodgkin’s disease patients in Japan. Cancer. 1996;77:186–92.PubMedCrossRef Tomita Y, et al. Epstein-Barr virus in Hodgkin’s disease patients in Japan. Cancer. 1996;77:186–92.PubMedCrossRef
18.
go back to reference Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–9.PubMedCrossRef Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–9.PubMedCrossRef
19.
go back to reference Ferme C, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. New Engl J Med. 2007;357:1916–27.PubMedCrossRef Ferme C, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. New Engl J Med. 2007;357:1916–27.PubMedCrossRef
20.
go back to reference Noordijk EM, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. J Clin Oncol. 2006;24:3128–35.PubMedCrossRef Noordijk EM, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. J Clin Oncol. 2006;24:3128–35.PubMedCrossRef
21.
go back to reference Engert A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2003;21:3601–8.PubMedCrossRef Engert A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2003;21:3601–8.PubMedCrossRef
22.
go back to reference Herbst C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95:494–500.PubMedCrossRef Herbst C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95:494–500.PubMedCrossRef
23.
go back to reference Itoh K, et al. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010;91:446–55.PubMedCrossRef Itoh K, et al. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010;91:446–55.PubMedCrossRef
24.
go back to reference Tan WY, et al. Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases. Ai zheng. 2007;26:1360–4.PubMed Tan WY, et al. Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases. Ai zheng. 2007;26:1360–4.PubMed
25.
go back to reference Franklin J, et al. Is the international prognostic score for advanced stage Hodgkin’s disease applicable to early stage patients? German Hodgkin lymphoma study group. Ann Oncol. 2000;11:617–23.PubMedCrossRef Franklin J, et al. Is the international prognostic score for advanced stage Hodgkin’s disease applicable to early stage patients? German Hodgkin lymphoma study group. Ann Oncol. 2000;11:617–23.PubMedCrossRef
26.
go back to reference Straus DJ, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173–86.PubMed Straus DJ, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173–86.PubMed
27.
go back to reference Garcia R, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer. 1993;68:1227–31.PubMedCrossRef Garcia R, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer. 1993;68:1227–31.PubMedCrossRef
28.
go back to reference Shipp M, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. New England J Med. 1993;329:987–94.CrossRef Shipp M, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. New England J Med. 1993;329:987–94.CrossRef
29.
go back to reference Siddiqui M, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006;134:596–601.PubMedCrossRef Siddiqui M, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006;134:596–601.PubMedCrossRef
30.
go back to reference Behl D, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007;137:409–15.PubMedCrossRef Behl D, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007;137:409–15.PubMedCrossRef
31.
go back to reference Kim DH, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007;21:2227–30.PubMedCrossRef Kim DH, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007;21:2227–30.PubMedCrossRef
32.
go back to reference Plonquet A, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with a IPI 2–3 diffuse large B-cell lymphoma. Ann Oncol. 2007;18:1209–15.PubMedCrossRef Plonquet A, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with a IPI 2–3 diffuse large B-cell lymphoma. Ann Oncol. 2007;18:1209–15.PubMedCrossRef
33.
go back to reference Cox MC, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49:1745–51.PubMedCrossRef Cox MC, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49:1745–51.PubMedCrossRef
34.
go back to reference Oki Y, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol. 2008;81:448–53.PubMedCrossRef Oki Y, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol. 2008;81:448–53.PubMedCrossRef
35.
go back to reference Porrata LF, et al. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2009;84:93–7.PubMedCrossRef Porrata LF, et al. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2009;84:93–7.PubMedCrossRef
36.
go back to reference Ray-Coquard I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.PubMedCrossRef Ray-Coquard I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.PubMedCrossRef
37.
go back to reference Saito T, et al. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res. 1999;5:1263–73.PubMed Saito T, et al. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res. 1999;5:1263–73.PubMed
38.
go back to reference Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature. 1999;402:255–62.PubMedCrossRef Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature. 1999;402:255–62.PubMedCrossRef
Metadata
Title
Clinical characteristics and prognostic factors in Chinese patients with Hodgkin’s lymphoma
Authors
Ying-Jie Zhu
Yue-Li Sun
Yi Xia
Wen-Qi Jiang
Jia-Jia Huang
Hui-Qiang Huang
Tong-Yu Lin
Zhong-Zhen Guan
Zhi-Ming Li
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9902-3

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.